Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 101–200 of 999
Metabolism the Difficile Way: The Key to the Success of the Pathogen Clostridioides difficile
Neumann-Schaal, M., Jahn, D., & Schmidt-Hohagen, K. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00219 · Cited by 154
Satokari, R., Mattila, E., Kainulainen, V., & Arkkila, P. E. T. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13009 · Cited by 156
Sholeh, M., Krůtová, M., Forouzesh, M., Mironov, S. P., Sadeghifard, N., Molaeipour, L., Maleki, A., & Kouhsari, E. (2020) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-020-00815-5 · Cited by 155
Hasegawa, M., Yada, S., Liu, M. Z., Kamada, N., Muñoz-Planillo, R., Do, N., Núñez, G., & Inohara, N. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.010 · Cited by 152
“Currently, elimination of C. difficile with vancomycin and/or metronidazole is the firstline treatment for C. difficile-infected patients (Rupnik et al., 2009).”
Accelerating resistance, inadequate antibacterial drug pipelines and international responses
Theuretzbacher, U. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.12.006 · Cited by 157
Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J. G., Ng, K. K.-S., MacKenzie, R., & Tanha, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.198754 · Cited by 153
Critical Role for MyD88-Mediated Neutrophil Recruitment during Clostridium difficile Colitis
Jarchum, I., Liu, M., Shi, C., Equinda, M., & Pamer, E. G. (2012) · Infection and Immunity · doi:10.1128/iai.00448-12 · Cited by 152
“difficile colitis is the most common cause of diarrhea among hospitalized patients (18).”
BackgroundInfluentialClostridium difficile: New Insights into the Evolution of the Pathogenicity Locus
Monot, M., Eckert, C., Lemire, A., Hamiot, A., Dubois, T., Tessier, C., Dumoulard, B., Hamel, B., Petit, A., Lalande, V., et al. (2015) · Scientific Reports · doi:10.1038/srep15023 · Cited by 167
The Regulatory Networks That Control Clostridium difficile Toxin Synthesis
Martin-Verstraete, I., Peltier, J., & Dupuy, B. (2016) · Toxins · doi:10.3390/toxins8050153 · Cited by 148
“difficile-associated disease range from mild diarrhea to severe life-threatening pseudo-membranous colitis and toxic megacolon associated with high mortality rates [5].”
BackgroundVirulence factors of Clostridium difficile and their role during infection
Janoir, C. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.10.009 · Cited by 196
Dingle, T. C., Mulvey, G. L., & Armstrong, G. D. (2011) · Infection and Immunity · doi:10.1128/iai.05305-11 · Cited by 180
“This strain is associated with outbreaks worldwide, increased disease severity, and increasing numbers of treatment failures (2, 28, 39).”
BackgroundReveles, K. R., Lee, G. C., Boyd, N. K., & Frei, C. R. (2014) · American Journal of Infection Control · doi:10.1016/j.ajic.2014.06.011 · Cited by 145
SpoIVA and SipL Are Clostridium difficile Spore Morphogenetic Proteins
Putnam, E. E., Nock, A. M., Lawley, T. D., & Shen, A. (2013) · Journal of Bacteriology · doi:10.1128/jb.02181-12 · Cited by 157
“difficile (9, 10) and can persist in the environment and within patients for extended periods of time (1, 3).”
BackgroundCyclic Di-GMP Riboswitch-Regulated Type IV Pili Contribute to Aggregation of Clostridium difficile
Bordeleau, E., Purcell, E. B., Lafontaine, D. A., Fortier, L.-C., Tamayo, R., & Burrus, V. (2015) · Journal of Bacteriology · doi:10.1128/jb.02340-14 · Cited by 143
“The Gram-positive spore-forming bacterium Clostridium difficile is the leading cause of nosocomial diarrhea and antibioticassociated colitis in hospital settings (1).”
BackgroundNie, L., Zhou, Q., Qiao, Y., & Chen, J. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.07.054 · Cited by 160
“Similarly, in a previous study, a mouse model of Clostridium difficile infection provided robust evidence supporting the causal link between the gut microbiota and host immune responses [54].”
ResultInvolvement of Reduced Microbial Diversity in Inflammatory Bowel Disease
Gong, D., Gong, X., Wang, L., Yu, X., & Dong, Q. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/6951091 · Cited by 142
“In other studies, increased microbiota diversity could be achieved in recipients who achieved remission after FMT [35, 38, 39].”
BackgroundPhysical activity induced alterations of gut microbiota in humans: a systematic review
Dziewiecka, H., Buttar, H. S., Kasperska, A., Ostapiuk–Karolczuk, J., Domagalska, M., Cichoń-Woźniak, J., & Skarpańska-Stejnborn, A. (2022) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-022-00513-2 · Cited by 168
“This bacterium is a major source of infectious diarrhea associated with toxin production in the host’s gastrointestinal tract [76, 77], especially in the elderly [78–80] and obese individuals [81, 82].”
BackgroundChemical and Stress Resistances of Clostridium difficile Spores and Vegetative Cells
Edwards, A. N., Karim, S. T., Pascual, R. A., Jowhar, L. M., Anderson, S. E., & McBride, S. M. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01698 · Cited by 141
Bile Salt Hydrolases: At the Crossroads of Microbiota and Human Health
Bourgin, M., Kriaa, A., Mkaouar, H., Mariaule, V., Jablaoui, A., Maguin, E., & Rhimi, M. (2021) · Microorganisms · doi:10.3390/microorganisms9061122 · Cited by 139
“difficile is a spore-forming pathogen that might colonize the gut of patients treated by broad-spectrum antibiotics [101,102].”
BackgroundHui, W., Li, T., Liu, W., Zhou, C., & Gao, F. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210016 · Cited by 140
RetractedOrth, P., Xiao, L., Hernandez, L. D., Reichert, P., Sheth, P. R., Beaumont, M., Yang, X., Murgolo, N., Ermakov, G., DiNunzio, E., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.560748 · Cited by 160
“Furthermore, the residues of TcdB defined herein as being involved in carbohydrate binding are based on the structure of TcdA bound to -Gal-(1,3)- -Gal-(1,4)- GlcNAcO(CH2)8CO2CH3, and it is possible that the TcdB ligand interacts with different residues (encompassing a smaller or larger surface area) within TcdB than…”
BackgroundMethodInfluentialClostridium difficile Infection
Heinlen, L. D., & Ballard, J. D. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181e939d8 · Cited by 179
Lim, S. K., Stuart, R. L., Mackin, K. E., Carter, G. P., Kotsanas, D., Francis, M. J., Easton, M., Dimovski, K., Elliott, B., Riley, T. V., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu203 · Cited by 140
“sordellii lethal toxin (TcsL) that cause cytotoxicity through inactivation of Rho/Ras small GTPases, and the target specificity of toxin B is determined by amino acids 365–516 [34].”
BackgroundAdaptive Strategies and Pathogenesis of Clostridium difficile from In Vivo Transcriptomics
Janoir, C., Denève, C., Bouttier, S., Barbut, F., Hoys, S., Caleechum, L., Chapetón-Montes, D., Pereira, F. C., Henriques, A. O., Collignon, A., et al. (2013) · Infection and Immunity · doi:10.1128/iai.00515-13 · Cited by 140
“difficile in the gut (1) can play a role in C.”
BackgroundInfluentialWotzka, S. Y., Nguyen, B. D., & Hardt, W. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.03.009 · Cited by 151
“difficile diarrhea, a major cause for antibiotic-associated diarrhea (Rupnik et al., 2009).”
The intestinal microbiota and susceptibility to infection in immunocompromised patients
Taur, Y., & Pamer, E. G. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283630dd3 · Cited by 139
“Unau 0951-7375 2013 Wolters Kluwer Health | Lippincott Williams & Wilk germinate and give rise to vegetative bacteria that replicate in the gut lumen and produce toxins A and B, which become internalized by colonic epithelial cells where they glucosylate Rho GTPases and lead to a loss of epithelial integrity [50].”
BackgroundPassmore, I. J., Letertre, M. P. M., Preston, M. D., Bianconi, I., Harrison, M. A., Nasher, F., Kaur, H., Hong, H. A., Baines, S. D., Cutting, S. M., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007191 · Cited by 138
“difficile infection (CDI) ranges from selflimiting diarrhoea to severe and life threatening pseudomembranous colitis[2].”
BackgroundEffects of short‐term endurance exercise on gut microbiota in elderly men
Taniguchi, H., Tanisawa, K., Sun, X., Kubo, T., Hoshino, Y., Hosokawa, M., Takeyama, H., & Higuchi, M. (2018) · Physiological Reports · doi:10.14814/phy2.13935 · Cited by 137
“Clostridium difficile is a major cause of infectious diarrhea due to the production of toxins into the host gut (Kelly and LaMont 2008; Rupnik et al. 2009).”
BackgroundPeptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis
Sorbara, M. T., & Philpott, D. J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01047.x · Cited by 136
“difficile and clinical exacerbation to diarrhea (141).”
BackgroundHasegawa, M., Kamada, N., Jiao, Y., Liu, M. Z., Núñez, G., & Inohara, N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200821 · Cited by 134
“in a significant group of patients, some of whom die of severe complications (1).”
BackgroundInfluentialClostridium Difficile Infection
Lübbert, C., John, E., & von Müller, L. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0723 · Cited by 178
Models for the study of Clostridium difficile infection
Best, E. L., Freeman, J., & Wilcox, M. H. (2012) · Gut Microbes · doi:10.4161/gmic.19526 · Cited by 135
“This can cause life threatening pseudomembranous colitis (PMC) which can result in toxic megacolon, bowel perforation sepsis shock and death.(5,6) Those at greatest risk for C.”
BackgroundInfluentialSelf-citationA Genomic Signature and the Identification of New Sporulation Genes
Abecasis, A. B., Serrano, M., Alves, R., Quintais, L. M. D. S. S. T., Pereira‐Leal, J. B., & Henriques, A. O. (2013) · Journal of Bacteriology · doi:10.1128/jb.02110-12 · Cited by 150
“The association of spore-forming bacteria with the GI tract also extends to pathogenic species, as well typified by the strictly anaerobic human and animal pathogen Clostridium difficile, which uses the anaerobic colon to propagate (producing two potent cytotoxins) and to form spores through which the organism dissemi…”
BackgroundInvolvement of Bacteria Other Than Clostridium difficile in Antibiotic-Associated Diarrhoea
Larcombe, S., Hutton, M. L., & Lyras, D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.02.001 · Cited by 143
Pavlidis, P., Powell, N., Vincent, R. P., Ehrlich, D., Bjarnason, I., & Hayee, B. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13333 · Cited by 132
“gen responsible for significant morbidity and mortality in hospitalised patients.(110) DCA and CDCA, by contrast, prevent C.”
Toll-Like Receptor 5 Stimulation Protects Mice from Acute Clostridium difficile Colitis
Jarchum, I., Liu, M., Lipuma, L., & Pamer, E. G. (2011) · Infection and Immunity · doi:10.1128/iai.01196-10 · Cited by 132
“Clostridium difficile is a Gram-positive, spore-forming rod that is acquired by oral ingestion of spores and occurs most commonly in hospitals and long-term health care facilities (27).”
BackgroundEckert, C., Emirian, A., Monnier, A. L., Cathala, L., de Montclos, H., Goret, J., Berger, P., Petit, A., de Chevigny, A., Jean‐Pierre, H., et al. (2014) · New Microbes and New Infections · doi:10.1016/j.nmni.2014.10.003 · Cited by 148
“This Gram-positive spore-forming bacterium is the major cause of hospital-acquired diarrhoea [1,2].”
BackgroundA probiotic yeast-based immunotherapy against Clostridioides difficile infection
Chen, K., Zhu, Y., Zhang, Y., Hamza, T., Yu, H., Fleur, A. S., Galen, J. E., Yang, Z., & Feng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax4905 · Cited by 138
“The recent rapid increase in the incidence of CDI and the associated disease severity stemming from the emergence of hypervirulent and antibiotic-resistant strains is alarming (60).”
BackgroundStrategies to improve reference databases for soil microbiomes
Choi, J., Yang, F., Stepanauskas, R., Cardenas, E., Garoutte, A., Williams, R. J., Flater, J. S., Tiedje, J. M., Hofmockel, K., Gelder, B., et al. (2016) · The ISME Journal · doi:10.1038/ismej.2016.168 · Cited by 166
“Firmicutes have been well-studied as pathogens, (Rupnik et al., 2009; Buffie and Pamer, 2013), likely resulting in their biased representation in our databases and consequently also biased annotations in soil studies.”
Pathogenicity and virulence of Clostridioides difficile
Buddle, J. E., & Fagan, R. P. (2022) · Virulence · doi:10.1080/21505594.2022.2150452 · Cited by 169
“The significant mortality associated with C. difficile typically arises from more severe manifestations, including pseudomembranous colitis, fulminant colitis, and toxic megacolon [4].”
Clostridium difficileInfection: A Comprehensive Review
Kachrimanidou, M., & Malisiovas, N. (2011) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2011.556598 · Cited by 129
“Toxinotyping is a RFLP-PCR based method for differentiating Clostridium difficile strains according to changes in their toxin genes when compared to the reference strain VPI 10463 (Rupnik et al., 2009).”
MethodCurrent understanding of antibiotic-associated dysbiosis and approaches for its management
Kesavelu, D., & Jog, P. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231154443 · Cited by 126
Cross-talk between bile acids and intestinal microbiota in host metabolism and health
Nie, Y.-F., Hu, J., & Yan, X.-H. (2015) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b1400327 · Cited by 126
“For example, CDI is the primary stimulus of recurrent ulcerative colitis (Rupnik et al., 2009).”
BackgroundClostridium difficile phages: still difficult?
Hargreaves, K. R., & Clokie, M. R. J. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00184 · Cited by 125
“…form of RNA based adaptive bacterial immunity to foreign DNA, Clostridium difficile infection is generally associated with the production of up to three toxins; toxin A and toxin B, which are encoded on a pathogenicity locus; the PaLoc, and the C. difficile binary toxin (CDT; Rupnik et al., 2009).”
BackgroundInfluentialMayer, M. J., Garefalaki, V., Spoerl, R., Narbad, A., & Meijers, R. (2011) · Journal of Bacteriology · doi:10.1128/jb.00439-11 · Cited by 126
“difficile is present in animals and has been detected in meat (33).”
BackgroundYu, H., Chen, K., Sun, Y., Carter, M., Garey, K. W., Savidge, T. C., Devaraj, S., Tessier, M. E., von Rosenvinge, E. C., Kelly, C. P., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00037-17 · Cited by 125
“CDI has variable clinical manifestations that range from asymptomatic colonization to fulminant colitis and death (3), which likely reflects differences in C.”
BackgroundStructural basis for recognition of frizzled proteins by Clostridium difficile toxin B
Chen, P., Tao, L., Wang, T., Zhang, J., He, A., Lam, K.-H., Liu, Z., He, X., Perry, K., Dong, M., et al. (2018) · Science · doi:10.1126/science.aar1999 · Cited by 126
Fidaxomicin Inhibits Spore Production in Clostridium difficile
Babakhani, F., Bouillaut, L., Gomez, A., Sears, P. S., Nguyen, L., & Sonenshein, A. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis453 · Cited by 147
“Clostridium difficile is a spore-forming anaerobic bacterium that has become a major cause of infectious diarrhea in healthcare settings and in the community [1].”
BackgroundSchoster, A., Kokotovic, B., Permin, A., Pedersen, P. D., Bello, F. D., & Guardabassi, L. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.02.006 · Cited by 151
“Clostridium difficile is an important enteropathogen of humans [1] and animals [2e4].”
BackgroundInactivation of clinically relevant pathogens by photocatalytic coatings
Dunlop, P., Sheeran, C. P., Byrne, J., McMahon, M. A. S., Boyle, M. A., & McGuigan, K. G. (2010) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2010.07.004 · Cited by 139
Luo, P., Liu, Y., Xia, Y., Xu, H., & Xie, G. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.11.013 · Cited by 121
How to: diagnose infection caused by Clostridium difficile
Gateau, C., Couturier, J., Coia, J. E., & Barbut, F. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.005 · Cited by 126
Russell, G., Kaplan, J., Ferraro, M., & Michelow, I. C. (2010) · PEDIATRICS · doi:10.1542/peds.2009-3363 · Cited by 120
Structural and Functional Analysis of the CspB Protease Required for Clostridium Spore Germination
Adams, C. M., Eckenroth, B. E., Putnam, E. E., Doublié, S., & Shen, A. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003165 · Cited by 145
“Although CDAD is primarily a toxin-mediated disease [3,4], the high cost and difficulty in treating C.”
BackgroundPostigo, R., & Kim, J. H. (2012) · Infection · doi:10.1007/s15010-012-0307-9 · Cited by 124
Peng, M., & Biswas, D. (2016) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1203286 · Cited by 136
“…in controlling the outgrowth and infections of pathogenic bacteria; for example, alteration in the composition of the gut microbiome following antibiotic treatment was associated with an overshedding of Clostridium difficile in the stool of infected mice (Lawley et al., 2008; Rupnik et al., 2009).”
BackgroundKe, S., Pollock, N. R., Wang, X., Chen, X., Daugherty, K., Lin, Q., Xu, H. J., Garey, K. W., Gonzales-Luna, A. J., Kelly, C. P., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1935186 · Cited by 124
“In our previous study(36), the four groups were named as (1) CDI-NAAT = CDI; (2) CarrierNAAT = Asymptomatic Carriage; (3) diarrhea NAAT-negative = Non-CDI Diarrhea and (4) no Diarrhea NAAT-Negative = Control.”
BackgroundMethodInfluentialFunctional Characterization of Clostridium difficile Spore Coat Proteins
Permpoonpattana, P., Phetcharaburanin, J., Mikelsone, A., Dembek, M., Tan, S., Brisson, M., Ragione, R. M. L., Brisson, A. R., Fairweather, N. F., Hong, H. A., et al. (2013) · Journal of Bacteriology · doi:10.1128/jb.02104-12 · Cited by 137
“Spores of Clostridium difficile are integral to the infection and disease caused by this Gram-positive pathogen (1).”
BackgroundEmerging insights on intestinal dysbiosis during bacterial infections
Pham, T. A. N., & Lawley, T. D. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.12.002 · Cited by 114
“difficile is also the leading cause of antibiotic-associated diarrhea in humans, whereby disease manifestation predominantly occurs following antibiotic disruption of the microbiota, or in patients with inflammatory bowel disease [16].”
BackgroundModeling infectious diseases and host-microbe interactions in gastrointestinal organoids
Bartfeld, S. (2016) · Developmental Biology · doi:10.1016/j.ydbio.2016.09.014 · Cited by 127
“Toxins produced by the bacterium then cause mild to severe gastroenteritis, but can also lead to severe complicated pseudomembranous colitis, characterized by inflammatory lesions and pseudomembranes in the colon (reviewed in Rupnik et al., 2009).”
BackgroundWhat Does the Talking?: Quorum Sensing Signalling Genes Discovered in a Bacteriophage Genome
Hargreaves, K. R., Kropinski, A. M., & Clokie, M. R. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085131 · Cited by 139
“The species is genetically diverse and different strains can produce up to three toxins, TcdA, TcdB and CDT, which are major virulence factors [16].”
BackgroundThe CodY pleiotropic repressor controls virulence in gram-positive pathogens
Stenz, L., Francois, P., Whiteson, K., Wolz, C., Linder, P., & Schrenzel, J. (2011) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2011.00812.x · Cited by 112
“All rights reserved (Rupnik et al., 2009).”
BackgroundPrevalence of Clostridium difficile in retailed meat in The Netherlands
Boer, E. D., Zwartkruis-Nahuis, A. J. T., Heuvelink, A., Harmanus, C., & Kuijper, E. J. (2010) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2010.11.007 · Cited by 114
Servin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-14 · Cited by 143
“However, these treatments can cause adverse effects outside or inside the gastrointestinal tract; one such effect that occurs if broadspectrum antibiotics are used is the emergence of Clostridium difficile-associated diarrhea resulting from an antibiotic-induced imbalance of the intestinal microbiota (508, 509).”
BackgroundJohann, P., Hamiot, A., Garneau, J. R., Boudry, P., Maikova, A., Hajnsdorf, E., Fortier, L., Dupuy, B., & Soutourina, O. A. (2020) · Communications Biology · doi:10.1038/s42003-020-01448-5 · Cited by 119
Spore Formation and Toxin Production in Clostridium difficile Biofilms
Semenyuk, E. G., Laning, M. L., Foley, J., Johnston, P. F., Knight, K. L., Gerding, D. N., & Driks, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087757 · Cited by 151
“CDI involves colonization of the gastrointestinal tract [14].”
BackgroundInfluentialClostridium difficile: Development of a novel candidate vaccine
Foglia, G., Shah, S., Luxemburger, C., & Pietrobon, P. J. F. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.056 · Cited by 113
Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns
Pamer, E. G. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.117 · Cited by 122
Heeg, D., Burns, D. A., Cartman, S. T., & Minton, N. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032381 · Cited by 111
“difficile infection (CDI) is estimated to affect more than 500,000 people per year in the USA alone and the spread of CDI has led to patient isolation, ward closures and even hospital closures [1].”
BackgroundPermpoonpattana, P., Hong, H. A., Phetcharaburanin, J., Huang, J.-M., Cook, J., Fairweather, N. F., & Cutting, S. M. (2011) · Infection and Immunity · doi:10.1128/iai.00130-11 · Cited by 125
“Recent estimates of CDAD in the United States suggest as many as 500,000 cases per year, with up to 20,000 deaths (32).”
BackgroundModulation of Toxin Production by the Flagellar Regulon in Clostridium difficile
Aubry, A. J., Hussack, G., Chen, W., KuoLee, R., Twine, S. M., Fulton, K. M., Foote, S. J., Carrillo, C. D., Tanha, J., & Logan, S. M. (2012) · Infection and Immunity · doi:10.1128/iai.00224-12 · Cited by 141
“difficile infection has been rapidly increasing in both Europe and North America, and this increase in infections has been associated with a significantly high mortality rate (2, 35).”
BackgroundJanežič, S., Ocepek, M., Zidarič, V., & Rupnik, M. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-48 · Cited by 118
“Background Intestinal diseases caused by Clostridium difficile, mainly after antibiotic treatment, ranges from mild self-limiting diarrhoea to life-threatening pseudomembranous colitis (PMC) and were until recently most commonly seen in hospitalized elderly patients [1].”
BackgroundSteele, J., Mukherjee, J., Parry, N. M., & Tzipori, S. R. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis669 · Cited by 111
“difficile infection (CDI) case and fatality rates since the early 2000s [1, 2].”
BackgroundSurface Layers of Clostridium difficile Endospores
Permpoonpattana, P., Tolls, E. H., Nadem, R., Tan, S., Brisson, A. R., & Cutting, S. M. (2011) · Journal of Bacteriology · doi:10.1128/jb.05182-11 · Cited by 118
“difficile-associated diarrhea (CDAD) in the United States suggest that there are as many as 500,000 cases per year, with up to 20,000 mortalities (29).”
BackgroundViswanathan, V. K., Mallozzi, M., & Vedantam, G. (2010) · Gut Microbes · doi:10.4161/gmic.1.4.12706 · Cited by 138
Bomers, M. K., van Agtmael, M. A., Luik, H., van Veen, M. C., Vandenbroucke‐Grauls, C. M. J. E., & Smulders, Y. M. (2012) · BMJ · doi:10.1136/bmj.e7396 · Cited by 109
A mobile genetic element profoundly increases heat resistance of bacterial spores
Berendsen, E. M., Boekhorst, J., Kuipers, O. P., & Wells-Bennik, M. H. J. (2016) · The ISME Journal · doi:10.1038/ismej.2016.59 · Cited by 110
“…the species are pathogenic and their spores have a pivotal role in the spread of infection (for example, Bacillus anthracis, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Clostridium botulinum; Ivanova et al., 2003; Read et al., 2003; Rupnik et al., 2009; Peck et al., 2011).”
BackgroundInterspecies Interactions between Clostridium difficile and Candida albicans
van Leeuwen, P. T., van der Peet, J. M., Bikker, F. J., Hoogenkamp, M. A., Oliveira Paiva, A. M., Kostidis, S., Mayboroda, O. A., Smits, W. K., & Krom, B. P. (2016) · mSphere · doi:10.1128/msphere.00187-16 · Cited by 104
“albicans on the regeneration of the intestinal flora after antibiotic-induced dysbiosis was recently shown (29), and reestablishment of a diverse gut microbiome is accompanied by a decreasing probability for the development of CDI (2, 10).”
BackgroundInfluentialThe microbial organ in the gut as a driver of homeostasis and disease
Lyte, M. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.10.025 · Cited by 112
“emergence of certain indigenous bacteria, notably Clostridium difficile that may occur as an untoward result of antibiotic therapy [54], be due to a failure of the host’s nervous system to provide the proper signals to allow the indigenous flora to recover quickly enough to prevent such pathogen overgrowth? Intestinal…”
BackgroundRansom, E. M., Ellermeier, C. D., & Weiss, D. S. (2015) · Applied and Environmental Microbiology · doi:10.1128/aem.03446-14 · Cited by 103
Cornely, O. A., Nathwani, D., Ivanescu, C., Odufowora-Sita, O., Retsa, P., & Odeyemi, I. A. O. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku261 · Cited by 113
Yang, Z., Schmidt, D., Liu, W., Li, S., Shi, L., Sheng, J., Chen, K., Yu, H., Tremblay, J. M., Chen, X., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu196 · Cited by 107
“comes, including mild diarrhea, fulminant disease, and death [2, 42].”
BackgroundA New Strategy for the Prevention of Clostridium difficile Infection
Howerton, A., Patra, M., & Abel‐Santos, E. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit068 · Cited by 103
“The rate of failure among first-line antibiotics in the treatment of CDI can be as high as 38% [3, 15].”
BackgroundJalanka, J., Mattila, E., Jouhten, H., Hartman, J., de Vos, W. M., Arkkila, P., & Satokari, R. (2016) · BMC Medicine · doi:10.1186/s12916-016-0698-z · Cited by 104
“The bacterium is the main etiological agent of antibiotic-associated diarrhoea, causing a major burden to the healthcare system [3–5].”
Highly Divergent Clostridium difficile Strains Isolated from the Environment
Janežič, S., Potočnik, M., Zidarič, V., & Rupnik, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167101 · Cited by 104
Evidence of In Vivo Prophage Induction during Clostridium difficile Infection
Meessen-Pinard, M., Sekulović, O., & Fortier, L. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.02275-12 · Cited by 111
“Sewage samples from two water treatment plants in Sherbrooke and human fecal samples from patients suffering from CDI collected over a 1-year period were screened for the presence of free phages.”
BackgroundInfluentialLee, S. T. M., Kahn, S. A., Delmont, T. O., Shaiber, A., Esen, Ö. C., Hubert, N. A., Morrison, H. G., Antonopoulos, D. A., Rubin, D. T., & Eren, A. M. (2017) · Microbiome · doi:10.1186/s40168-017-0270-x · Cited by 102
Clostridium difficile infection in humans and animals, differences and similarities
Keessen, E. C., Gaastra, W., & Lipman, L. J. A. (2011) · Veterinary Microbiology · doi:10.1016/j.vetmic.2011.03.020 · Cited by 126
Clostridium difficile infection: Evolution, phylogeny and molecular epidemiology
Elliott, B., Androga, G. O., Knight, D. R., & Riley, T. V. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.12.018 · Cited by 124
“Although considered a nosocomial disease, CDI has also begun to emerge in the community, and in younger individuals who lack the traditional risk factors, often with a higher AC C EP TE D M AN U SC R IP T incidence in females (Aronsson et al., 1985; McDonald et al., 2006; Rupnik et al., 2009).”
BackgroundEpidemiology and control of Clostridium difficile infections in healthcare settings
Barbut, F., Jones, G., & Eckert, C. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834748e5 · Cited by 99
Yang, Z., Ramsey, J. P., Hamza, T., Zhang, Y., Li, S., Yfantis, H. G., Lee, D. K., Hernandez, L. D., Seghezzi, W., Furneisen, J. M., et al. (2014) · Infection and Immunity · doi:10.1128/iai.02897-14 · Cited by 103
“The symptoms of CDI range from asymptomatic carriage or mild diarrhea to fatal pseudomembranous colitis, colonic rupture, and death (6, 7).”
BackgroundMcAllister, K. N., Bouillaut, L., Kahn, J. N., Self, W. T., & Sorg, J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-15236-5 · Cited by 110
Biofilm formation by Clostridium difficile
Đapa, T., & Unnikrishnan, M. (2013) · Gut Microbes · doi:10.4161/gmic.25862 · Cited by 126
“The clinical symptoms can range from mild or severe diarrhea to serious inflammatory conditions, including pseudomembranous colitis.(1) Recently it was demonstrated that transmission of clostridial disease occurs through spores.”
BackgroundUnterer, S., Strohmeyer, K., Kruse, B. D., Sauter‐Louis, C., & Hartmann, K. (2011) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2011.00765.x · Cited by 104
Reconsidering the Sporulation Characteristics of Hypervirulent Clostridium difficile BI/NAP1/027
Burns, D. A., Heeg, D., Cartman, S. T., & Minton, N. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024894 · Cited by 128
“In the United States of America alone, CDI is estimated to affect over 500,000 people each year and cost the healthcare system over $3 billion per year [1,2].”
BackgroundMetabolic Adaptations to Infections at the Organismal Level
Troha, K., & Ayres, J. S. (2020) · Trends in Immunology · doi:10.1016/j.it.2019.12.001 · Cited by 97
“difficile infection is prior antibiotic use (28).”
Abt, M. C., Buffie, C. G., Sušac, B., Becattini, S., Carter, R. A., Leiner, I., Keith, J. W., Artis, D., Osborne, L. C., & Pamer, E. G. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6663 · Cited by 94
Knight, D. R., Thean, S. K., Putsathit, P., Fenwick, S., & Riley, T. V. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.03951-12 · Cited by 102
“Reports from North America and, to a lesser extent, Europe describe C. difficile as being isolated from cattle and meat destined for human consumption (13–15).”
BackgroundInfluentialLocher, H. H., Seiler, P. J., Chen, X., Schroeder, S., Pfaff, P., Enderlin, M., Klenk, A., Fournier, E., Hubschwerlen, C., Ritz, D., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01830-13 · Cited by 98
“difficileassociated diarrhea, is a major health care problem and a leading cause of morbidity and mortality in elderly hospitalized patients (1, 2).”
BackgroundA novel approach to generate a recombinant toxoid vaccine against Clostridium difficile
Donald, R. G. K., Flint, M., Kalyan, N. K., Johnson, E. W., Witko, S. E., Kotash, C. S., Zhao, P., Megati, S., Yurgelonis, I., Lee, P. K., et al. (2013) · Microbiology · doi:10.1099/mic.0.066712-0 · Cited by 103
“Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11 On: Fri, 02 Nov 2018 13:54:58 A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile Robert G. K. Donald,1 Mike Flint,2 Narender Kalyan,1 Erik Johnson,1 Susan E. Witko,1 Cheryl Kotash,1 Ping Zhao,1 Shakuntala Megati,1 Irin…”
BackgroundInfluential
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.